Abstract
Introduction:
In the early 1990s it was discovered that the naturally occurring estrogen metabolite, 2-methoxyestradiol, inhibited cell proliferation and angiogenesis independently from the estrogen receptor [1] . It is believed that the mechanism of action for this compound is through an interaction with the colchicine binding site of β-tubulin impairing microtubule remodeling, inducing metaphase arrest and apoptosis [1] [2] [3] [4] [5] [6] [7] . Clinical trials of 2-methoxyestradiol as a cancer treatment were halted due to an extremely low plasma concentration in patients despite high dose administration indicating a lack of oral bioavailability and high susceptibility to clearance by liver enzymes [8] .
Independently it was discovered that 2-substituted estrone sulfamates, a class of steroid sulfatase inhibitors were antiproliferative towards cancer cells [9] [10] [11] . The cytotoxic properties of the sulfamates were similar to those seen in 2-methoxyestradiol. Numerous studies have been employed to identify the structure-activity relationships associated with various derivatives of the 2-substituted estrone sulfamates. Among the most promising were 2-ethylestradiol-3,17-O,O-bis-sulfamate (compound 14), 2-ethylestrone 3-O-sulfamate (compound 15), and 2-ethylestradiol 3-Osulfamate (compound 16) (Fig. 1 ) [12] [13] [14] . Compound 14 was shown to be a highly effective anti-proliferative agent in vitro with a mean 50% growth inhibition concentration (GI 50 ) of 0.018 μM across the National Cancer Institute's (NCI) 60 cancer cell line panel and in vivo in both breast and prostate cancer xenografted mice [12, 14] . Compound 15 also proved to be an effective anti-proliferative with a mean GI 50 of 0.014 μM in the NCI panel. Compound 16 was shown to have anti-angiogenic properties, was characterized in vitro with a mean GI 50 of 0.016 μM in the NCI panel, and demonstrated high bioavailability and growth inhibition in vivo with estrogen receptor negative breast cancer xenografted mice [13] . The benefits of these sulfamated compounds lie in both their high oral bioavailability and their capacity to circumvent first pass liver metabolism by reversibly attaching to carbonic anhydrase II in red blood cells protecting it from clearance [15, 16] .
Carbonic anhydrase (CA) is a zinc metalloenzyme that catalyzes the reversible interconversion of carbon dioxide and water into bicarbonate and a proton. There are fourteen CA isoforms expressed in humans serving a wide variety of functions including respiration, pH homeostasis, and fluid retention [17] . CA II is a cytoplasmic isozyme expressed ubiquitously across most cell types including erythrocytes where it is essential for respiration.
CA IX is a membrane-bound CA normally only expressed in cells requiring high extracellular pH such as gastric epithelial cells [18] . However in many cancers this protein is overexpressed during solid tumor growth, contributing carbonate concentration. Inhibitor concentrations ranged up to 8 μM and the data were processed using the Henderson method for tight-binding inhibitors [26] . Experimental values can be found in Table 1 .
Crystallization and Data Collection-Crystals of CA II and CA IX mimic complexed with the compounds were obtained by co-crystallization using the hanging drop vapor diffusion method [27] . Crystallization conditions are as follows: 5 μl of 15 mg ml -1 of protein and 5 μl of 1.4 M sodium citrate, 100 mM Tris-Cl, and 7.5 mM of compound were suspended over 1 ml of 1.4 M sodium citrate and 100 mM Tris-Cl. The crystallization pH for compounds 15
and 16 was pH 8 and for 14 was pH 9. Crystals were soaked for 10 seconds in a cryo-protectant solution of 0.9 M sodium citrate, 100 mM Tris-Cl pH 8, 20% glycerol. Initial structure solutions of CA II with 15 and 16 did not give sufficient density for compound modeling. Additional crystals were soaked in a solution of 1 M sodium citrate, 50
mM Tris-Cl, pH 8, 20% glycerol and 10 mM of the compound. The crystals were flash-cooled to 100 K in a gas nitrogen cryostream. Data was collected in house using a Rigaku RU-300 rotating copper anode generator (λ=1.5418 Å) on a R-AXIS IV++ image plates. The crystal-to-detector distance was 80 mm, with 1° oscillation width and 300 s exposure times. The data was merged using HKL 2000 [28] .
Structure Determination-All the crystal structures were determined by molecular replacement methods using wt CA II (PDB code 2ili) [29] . The initial rigid body, individual coordinate and atomic displacement parameter
(ADP) refinement was performed in PHENIX.refine [30] . F o -F c maps provided phase-unbiased electron density for the respective bound inhibitors (Supplemental Fig. 1 ). The PRODRG server was used to generate coordinates and restraints for inhibitor modeling [31] . Refinement continued with alternating rounds in PHENIX.refine and manual model building in COOT [30, 32] . Ordered solvent was added, as well as TLS refinement and riding hydrogens.
Refinement of the structures continued until the R cryst and R free converged. The compound-enzyme interactions were determined using LIGPLOT [33] . The PDB IDs, data, refinement, and final model statistics for the five novel structures are given in Supplemental Table 1 . Ligand-protein interactions are listed in Supplemental Table 2 .
Energy Calculations-All binding energies were calculated using the PISA server [34] . The wt CA IX values were derived by least-squares superposition of chain A of CA IX (PDB ID 3iai) onto either CA II or CA IX mimic.
The glycerol and acetazolamide from 3iai was removed and replaced by the superposed compound coordinates. ΔG values in kcal/mol are listed in Table 1 .
Results
Comparison Between wild-type CA IX and CA IX mimic. Recently the structure of wt CA IX in complex with acetazolamide (AZM) was determined [22] . This provides the opportunity to assess the usefulness of the CA II Inhibition. Assays measuring the inhibition of 18 O exchange catalyzed by CA II and CA IX mimic were conducted on compounds 14, 15, and 16 (Table 1) . It is of note that esterase inhibition assays of compound 14 were performed with CA II previously with an inhibition constant of 230 ± 60 nM [23] . However, this test measures the steady-state inhibition of the esterase activity of CA and the current studies measure inhibition of carbon dioxide interconversion with bicarbonate at chemical equilibrium. These very different methods yield somewhat different values of inhibition constants.
Assays using 18 O exchange were carried out to provide inhibition constants for analysis. Compound 14 produced very similar inhibition constants between CA II, 880 ± 70 nM, and CA IX mimic, 680 ± 40 nM.
Compound 15 had K i s of 440 ± 50 nM for CA II and 590 ± 30 for CA IX mimic, revealing a small 34% decrease in affinity. In contrast compound 16 showed the most distinctive isozyme specificity with a K i of 180 ± 10 nM for CA II and 2100 ± 220 nM for the CA IX mimic, a nearly 12-fold difference. Figure 2B , C, E). The structure in CA IX mimic showed a clearly defined, zincbound ligand that refined to an occupancy of 85% (Supplemental Figure 1C) . Additionally another low occupancy (58%) molecule of 15 was identified (Supplemental Figure 1D ).
The density of 15 in CA II was less ordered. The experiment was repeated with 15 additionally added in the cryoprotectant, improving the density enough for modeling at an occupancy of 60% with alternate water positions coordinating with those observed in unbound CA II. Though the density is contoured at a low sigma, most of the molecule can be seen clearly in an averaged kick map contoured to 0.8 σ (Supplemental Figure 1B) [35]. There was also a GOL molecule located in the active site.
In the two structures the orientation of the sulfamate is similar, leading to similar distances in the Zn In CA II residue 67 is an asparagine, which is too short to coordinate to this O17. This bond is fairly strong in the CA IX mimic with a distance of 2.9 Å to the water and 2.7 Å from the water to the Gln 67.
A second molecule of 15 is seen sitting on the exterior of the active site in the CA IX mimic-15 complex ( Figure 2E and Supplemental Figure 1D This discernable difference in affinity reinforces the feasibility of developing an effective and isozyme-specific CA inhibitor, though in this case the specificity is for CA II rather than the anti-cancer target CA IX. That a single water-mediated hydrogen bond can confer a pronounced change in K i strengthens the assertion that water should be a consideration in structure-based drug design. Conceivably an inhibitor of similar length with more hydrophilic properties along the backbone could achieve a highly desired, CA IX specific inhibitor that could be used to combat solid tumor growth in numerous cancers.
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